All Regulatory Area articles
-
Industry newsBurkina Faso gives R21 malaria vaccine approval in children
Burkina Faso’s regulatory agency – Agence Nationale de la Regulation Pharmaceutique – has approved the R21/Matrix-M malaria vaccine for children.
-
Industry newsGlobal life sciences consultancy created from SSI/NDA merger
US-based SSI Strategy buys Sweden-based regulatory affairs consultancy NDA Group AB; Strömquist stays on as President of NDA unit.
-
CPD SupplementQualification of stride velocity endpoint in Duchenne Muscular Dystrophy
In April 2019, the Committee for Medicinal Products for Human Use (CHMP) issued a qualification opinion on stride velocity as an endpoint in clinical studies of medicines for the treatment of Duchenne Muscular Dystrophy (DMD).[1] Mutations in the dystrophin gene cause this inherited, x-linked disorder which causes progressive muscle weakness ...